Skip Navigation


JAC Advance Access originally published online on October 29, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/6/887    most recent
dkg481v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herbst, M. M.
Right arrow Articles by Pyles, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herbst, M. M.
Right arrow Articles by Pyles, R. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 887-889
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Immunostimulatory CpG treatment for genital HSV-2 infections

Melissa M. Herbst and Richard B. Pyles*

Sealy Center for Vaccine Development and Department of Pediatrics, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0436, USA

Keywords: herpes simplex virus, genital herpes, immunostimulatory sequences, CpG motif, topical microbicides, vaginal microbicides, sexually transmitted diseases

The first 150 words of the full text of this article appear below.

Genital herpes simplex virus type 2 (HSV-2) infection is one of the most common sexually transmitted diseases,1 infecting approximately 20–30% of US adults.2 Despite efforts to reduce HSV-2 transmission rates through behavioural modifications and chemical interventions, a 30% increase in seroprevalence was reported recently3 indicating the ongoing nature of this epidemic and the inadequacies of current therapeutic approaches. Primary HSV-2 infections produce vesiculo-ulcerative lesions and the establishment of a life-long latent infection in innervating sensory neurons.4 Recurrent ulcerative lesions produced by viral reactivation predispose to human immunodeficiency virus type 1 (HIV-1) infection and colonization by other pathogens.5,6 Viral reactivation also results in asymptomatic viral shedding episodes that are a major factor in viral transmission.7 The majority of HSV-2-seropositive people are unaware that they are infected and can transmit the virus in the absence of clinically apparent lesions further complicating control of infection.7 Such asymptomatic viral shedding events occur as frequently . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
N. Gill and A. A. Ashkar
Overexpression of Interleukin-15 Compromises CD4-Dependent Adaptive Immune Responses against Herpes Simplex Virus 2
J. Virol., January 15, 2009; 83(2): 918 - 926.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. Gill, K. L. Rosenthal, and A. A. Ashkar
NK and NKT Cell-Independent Contribution of Interleukin-15 to Innate Protection against Mucosal Viral Infection
J. Virol., April 1, 2005; 79(7): 4470 - 4478.
[Abstract] [Full Text] [PDF]